New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients

Clin Rheumatol. 2006 Nov;25(6):929-33. doi: 10.1007/s10067-005-0097-x.

Abstract

Therapies aimed at inhibiting tumor necrosis factor, a proinflammatory cytokine implicated in autoimmune disease, are effective for rheumatoid arthritis (RA) and Crohn's disease. We report two patients who newly developed multiple demyelinating lesions in the central nervous system in the course of infliximab therapy for active RA. Neurological symptoms and the number of gadolinium-diethylenetriamine pentaacetic acid-enhanced lesions in magnetic resonance imaging gradually diminished with steroid treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Central Nervous System Diseases / chemically induced*
  • Central Nervous System Diseases / diagnosis
  • Central Nervous System Diseases / drug therapy
  • Contrast Media
  • Demyelinating Diseases / chemically induced*
  • Demyelinating Diseases / diagnosis
  • Demyelinating Diseases / drug therapy
  • Female
  • Gadolinium DTPA
  • Humans
  • Infliximab
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Steroids / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Contrast Media
  • Steroids
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Gadolinium DTPA